

Special Issue

Design and Synthesis of Novel Antibiotics, 2nd Edition

Message from the Guest Editor

Building on the success of the first volume, which featured eight insightful articles, this second volume of the Special Issue "Design and Synthesis of Novel Antibiotics" continues to address the critical challenge of antimicrobial resistance. As resistance to existing antibiotics has escalated, the need for innovative therapeutic solutions has become increasingly urgent. This volume aims to showcase cutting-edge research in the development of novel antibiotics, focusing on innovative design strategies, synthesis methods, and the evaluation of the efficacy and safety of new compounds. We invite contributions that highlight structural advancements, biological activity assessments, and cytotoxicity studies, furthering our collective efforts to combat antimicrobial resistance.

Guest Editor

Dr. Kenneth Ikenna Onyedibe

Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, IN 47907, USA

Deadline for manuscript submissions

20 January 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/236518

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)